Tier 4 — mechanistic

Higher Dietary Quercetin Intake Is Associated with Lower Risk of Adverse Outcomes among Individuals with Inflammatory Bowel Disease in a Prospective Cohort Study

Tianyu Wang, Shi-Yuan Lu, Lintao Dan, Yuhao Sun, Tian Fu, Li Tian, Jie Chen
The Journal of nutrition 2024 154(6):1861-1868

Bibliography

PubMed
PMID 38677479
DOI
10.1016/j.tjnut.2024.04.025
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignProspective observational dietary cohort
ModelHuman observational research
Sample2,293 UK Biobank participants with inflammatory bowel disease
InterventionEstimated dietary quercetin intake
DurationMean follow-up 9.6 years
EndpointsEvents and survival

What the study showed, in plain terms

Published in 2024, this source examined gut and intestinal health. Design: Prospective observational dietary cohort. Sample/model: 2,293 UK Biobank participants with inflammatory bowel disease. The exposure or intervention was Estimated dietary quercetin intake. Follow-up or treatment period: Mean follow-up 9.6 years.

Higher intake was associated with lower mortality and lower surgery risk overall, with some differences by disease subtype.

Association is not causation. Diet quality, residual confounding, and intake measurement prevent attributing the outcomes to quercetin supplements.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Gut Health: Microbiome and Barrier Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Higher intake was associated with lower mortality and lower surgery risk overall, with some differences by disease subtype.
  • The recorded outcome domains were Events and survival.
  • The exposure was observed rather than assigned as an isolated supplement treatment.

What this study can and cannot tell us

  • Association is not causation. Diet quality, residual confounding, and intake measurement prevent attributing the outcomes to quercetin supplements.
  • Confounding, dietary patterns, illness, medication use and reverse causation can influence an association. Blood or dietary concentrations do not identify the effect of starting a capsule.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology